A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaMaria Domenica Cappellini, Antonio Piga, Mohamed Béjaoui et al.|New England Journal of Medicine|2020Cited by 320
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 studyKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|The Lancet|2022Cited by 87
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) TransfusionsMaria Domenica Cappellini, Antonio Piga, Vip Viprakasit et al.|Blood|2018Cited by 14
Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|Blood|2021Cited by 7
S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDYMaria Domenica Cappellini, Vip Viprakasit, Alì Taher et al.|HemaSphere|2022Cited by 6